+14%

est. 2Y upside i

HealthcareSeries C

Rank

#1741

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

High-risk opportunity: missing valuation data forces assumptions.

Last updated: July 4, 2026

Bull (20%)+140%

FDA approval and successful commercialization drive exit to $1.5B, netting 140% upside after 20% dilution.

Base (55%)+20%

Moderate progress leads to $750M exit, netting 20% upside after 20% dilution.

Bear (25%)-100%

Regulatory failure or insufficient market adoption leads to exit below $250M total funding, resulting in -100% return for common stock.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

50%

Total funding of $250M vs assumed entry valuation of $500M results in 50% preference overhang, severely diluting common equity in downside scenarios.

Dilution Risk

high

Clinical-stage company will likely require additional capital, further diluting existing shareholders.

Secondary Liquidity

limited

Pre-IPO shares traded on platforms like UpMarket, but liquidity is limited.

Questions to Ask at the Interview

Strategic questions based on Loyalfordogs's data — designed to show you've done your homework.

  • 1

    “How does Loyal plan to achieve market penetration given the long FDA timeline?”

  • 2

    “What is the company's strategy for extending runway beyond the $100M Series C?”

  • 3

    “How does the equity package compare to typical biotech pre-IPO offers in terms of liquidity and preference?”

Community

Valuation Sentiment

Our model estimates +14% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.